Alosetron HCl - CAS 122852-69-1
Catalog number:
122852-69-1
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C17H18N4O. HCl
Molecular Weight:
330.81
COA:
Inquire
Targets:
5-HT Receptor
Description:
The hydrochloride salt form of Alosetron which is an effective 5-HT3 receptor antagonist and could be commonly used against irritable bowel syndrome.
Publictions citing BOC Sciences Products
  • >> More
Purity:
> 95%
Appearance:
White to Pale Yellow Solid
Synonyms:
2,3,4,5-Tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1H-pyrido[4,3-b]indol-1-one Hydrochloride;
Solubility:
DMSO:> 3 mg/ml; methanol: > 3 mg/ml
Storage:
-20ºC Freeze
MSDS:
Inquire
Application:
The hydrochloride salt form of Alosetron which is an effective 5-HT3 receptor antagonist and could be commonly used against irritable bowel syndrome.
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Quantity:
Milligrams-Grams
Melting Point:
>270 ˚C
InChIKey:
FNYQZOVOVDSGJH-UHFFFAOYSA-N
InChI:
InChI=1S/C17H18N4O.ClH/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2;/h3-6,10H,7-9H2,1-2H3,(H,18,19);1H
Canonical SMILES:
CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C.Cl
1.Development of a Forced Degradation Profile of Alosetron by Single Mode Reversed-Phase HPLC, LC-MS, and its Validation.
Karthik Y1, Babu B1, Meyyanathan SN1. Sci Pharm. 2014 Dec 29;83(2):311-20. doi: 10.3797/scipharm.1411-07. eCollection 2015.
Determination of alosetron in the presence of its degradation products was studied and validated by a novel HPLC method. The separation of the drug and its degradation products was achieved with the Jones Chromatography C18 analytical column (150 mm x 4.6 mm; 3 µm) with a stationary phase in isocratic elution mode. The mobile phase used was 0.01 M ammonium acetate, pH-adjusted to 3.5 with glacial acetic acid and acetonitrile in the ratio of 75:25 (V/V) at a flow rate of 1 ml/min and UV detection was carried out at 217 nm. Further, the drug was subjected to stress studies for acidic, basic, neutral, oxidative, and thermal degradations as per ICH guidelines and the drug was found to be labile in base hydrolysis and oxidation, while stable in acid, neutral, thermal, and photolytic degradation conditions. An MS study has been performed on the major degradation products to predict the degradation pathway of alosetron. The method provided linear responses over the concentration range of 100-1500 ng/ml and regression analysis showed a correlation coefficient value (r(2)) of 0.
2.Novel pharmacological therapies for irritable bowel syndrome.
Corsetti M1, Whorwell P2. Expert Rev Gastroenterol Hepatol. 2016 Mar 18:1-9. [Epub ahead of print]
Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder, which represents a major cost to healthcare services. Current pharmacological treatment includes fibre supplements, antispasmodics, laxatives, loperamide and antidepressants. This article reviews the novel pharmacological treatments already or recently approved for patients with IBS-C (lubiprostone, linaclotide) and IBS-D (alosetron, ramosetron, rifaximin, eluxadoline). Furthermore, results for drugs in development (plecanatide, ibudutant and ebastine) or used in chronic constipation or for other indications, with potential application in IBS (prucalopride, elobixibat, mesalazine, ondansetron and colesevelam) are also reviewed.
3.Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome.
Lacy BE1. Int J Gen Med. 2016 Feb 11;9:7-17. doi: 10.2147/IJGM.S93698. eCollection 2016.
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders worldwide. The economic impact of IBS on the health care system is substantial, as is the personal impact on patients. Patients with diarrhea-predominant IBS (IBS-D) comprise a substantial proportion of the overall IBS population. Primary care providers are often the first point of contact for patients with IBS-D and can accurately diagnose IBS after a careful history and examination without extensive diagnostic tests. Several pharmacologic treatments (eg, loperamide, alosetron, and antidepressants) and non-pharmacologic treatments (eg, dietary modification and probiotics) are available for IBS-D, but restrictions on use (eg, alosetron) or the lack of controlled trial data showing reductions in both global and individual IBS-D symptoms (eg, bloating, pain and stool frequency) emphasize the need for alternative treatment options. Two newer medications (eluxadoline and rifaximin) were approved in May 2015 for the treatment of IBS-D, and represent new treatment options for this common gastrointestinal condition.
4.Novel Therapies in IBS-D Treatment.
Nee J1, Zakari M2, Lembo AJ2. Curr Treat Options Gastroenterol. 2015 Dec;13(4):432-40. doi: 10.1007/s11938-015-0068-5.
OPINION STATEMENT: Irritable bowel syndrome (IBS) is a common gastrointestinal disease characterized by abdominal pain and change in bowel habits. IBS diarrhea predominant (IBS-D), which is arguably the most common subset of IBS, is also associated with rectal urgency, increased frequency, abdominal bloating, and loose to watery stools. Current treatments for diarrhea include mu-opioid agonists (i.e., loperamide, lomotil) and bile acid sequestrants (i.e., cholestyramine) while treatments for abdominal pain include antispasmodics (i.e., hyoscyamine, dicyclomine) and tricyclic antidepressants (i.e., amitriptyline). There are currently 3 FDA-approved treatments for IBS-D, which have been shown to improve both abdominal pain and diarrhea. Alosetron was initially approved by FDA 2000; however, its use is now limited to women with severe IBS-D symptoms refractory to other treatment. Eluxadoline, a mixed mu-opioid agonist, and rifaximin, a broad spectrum gut specific antibiotic, were both FDA approved in 2015.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related 5-HT Receptor Products


CAS 122852-43-1 Alosetron (Z)-2-butenedioate

Alosetron (Z)-2-butenedioate
(CAS: 122852-43-1)

The maleic acid salt form of Alosetron which is an effective 5-HT3 receptor antagonist and could be commonly used against irritable bowel syndrome.

CAS 439239-90-4 Lasmiditan

Lasmiditan
(CAS: 439239-90-4)

Lasmiditan is a high-affinity, highly selective 5-HT1F receptor agonist(Ki=2.1 nM) for the treatment of acute migraine.

CAS 916918-84-8 Ansofaxine hydrochloride

Ansofaxine hydrochloride
(CAS: 916918-84-8)

Ansofaxine hydrochloride is a triple reuptake inhibitor of serotonin (IC50= 723 nM), dopamine (IC50= 491 nM) and norepinephrine reuptake (IC50= 763 nM).

CAS 839713-36-9 Nelotanserin

Nelotanserin
(CAS: 839713-36-9)

Nelotanser is Serotonin 2A receptor inverse agonist. In Aug 2016, Axovant Sciences initiated a phase-II clinical trial in Lewy body disease in USA.

Revexepride
(CAS: 219984-49-3)

Revexepride, also referred as SSP-002358, is a very selective and potent 5-HT4 receptor agonist and a novel prokinetic that stimulates gastrointestinal motility...

CAS 17321-77-6 Clomipramine HCl

Clomipramine HCl
(CAS: 17321-77-6)

Clomipramine HCl is a hydrochloride salt of clomipramine which is a serotonin transporter (SERT), norepinephrine transporter (NET) dopamine transporter (DAT) bl...

CAS 133454-47-4 Iloperidone

Iloperidone
(CAS: 133454-47-4)

Iloperidone displays high affinity (Ki < 10 nM) for norepinephrine alpha(1)-adrenoceptors, dopamine D(3) and serotonin 5-HT(2A) receptors.

CAS 135159-51-2 Sarpogrelate hydrochloride

Sarpogrelate hydrochloride
(CAS: 135159-51-2)

The hydrochloride salt form of Sarpogrelate, a 5-HT2 antagonist, could be used as an antiplatelet agent and other sorts of disease like angina pectoris, diabete...

CAS 122883-93-6 Ziprasidone Hydrochloride

Ziprasidone Hydrochloride
(CAS: 122883-93-6)

The hydrochloride salt form of Ziprasidone which is an antagonism of both serotonin and dopamine receptor and could be effective against schizophrenia.

CAS 192927-92-7 LY310762

LY310762
(CAS: 192927-92-7)

LY310762 has a higher affinity for the guinea pig 5-HT1D receptor than for the 5-HT1B receptor. LY310762 potentiates the potassium-induced [3H]5-HT outflow from...

CAS 85650-57-3 Setiptiline maleate

Setiptiline maleate
(CAS: 85650-57-3)

Setiptiline maleate is a serotonin receptor antagonist. It is used as a tetracyclic antidepressant (TeCA) and acts as a noradrenergic and specific serotonergic ...

Lu AE58054
(CAS: 467459-31-0)

Lu AE58054 is a selective and high affinity 5-HT6 receptor antagonist as promising treatment for cognitive disorders.

Ziprasidone-d8
(CAS: 1126745-58-1)

A labelled form of Ziprasidone which is an antagonist of both 5-HT and dopamine receptor and it has been studied to show effective antipsychotic activity.

CAS 119193-37-2 LY 278584

LY 278584
(CAS: 119193-37-2)

LY 278584 is a 5-HT3-receptor antagonist and no detailed information has been published yet.

CAS 85650-56-2 Asenapine

Asenapine
(CAS: 85650-56-2)

Asenapine is a high-affinity antagonist of serotonin, norepinephrine, dopamine and histamine receptors, used for the treatment of schizophrenia and acute mania ...

CAS 85650-56-2 Asenapine Maleate

Asenapine Maleate
(CAS: 85650-56-2)

Asenapine Maleate is a 5-HT receptor antagonist used for the treatment of acute schizophrenia and bipolar mania. It is a second-generation (atypical) antipsycho...

Elzasonan citrate
(CAS: 361343-20-6)

Elzasonan citrate is a selective 5-hydroxytryptamine 1B receptor antagonist for treat patients with major depressive disorder and obsessive compulsive disorder.

SUVN-502
(CAS: 701205-60-9)

SUVN-502 is a 5-HT6 receptor antagonist originated by Suven Life Sciences. It has >1200-fold selectivity over 5-HT2A receptor with a superior profile that diffe...

CAS 329218-11-3 Quetiapine sulfoxide dihydrochloride

Quetiapine sulfoxide dihydrochloride
(CAS: 329218-11-3)

Quetiapine sulfoxide dihydrochloride, a metabolite of Quetiapine, has antipsychotic effect.

(R)-6-Hydroxybuspirone hydrochloride
(CAS: 477930-30-6)

(R)-6-Hydroxybuspirone is a major active metabolite of Buspirone. (R)-Enantiomer showed higher affinity and selectivity for the 5HT1A receptor compared to the ...

Chemical Structure

CAS 122852-69-1 Alosetron HCl

Quick Inquiry

Verification code

Featured Items